1. Brown J, O´Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2:CD001396. Available from: doi: 10.1002/14651858.CD001396.pub2.
2. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32(1):119-132. Available from: DOI:10.1017/s0033291701004925
3. Halbreich U, Backstrom T, Eriksson E, O´Brien S, Calil H, Ceskova E et al. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder – clinical procedures and research perspectives. Gynecol Endocrinol 2004; 19: 320–333. Available from: https://doi.org/10.1080/09513590601167969
4. Eriksson E, Ekman A, Sinclair S, Sörvik K, Ysander C, Mattson U-B et al. Escitalopram Administrated in the luteal phase experts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol. 2008; 28
(2):195-202. Available from: doi: 10.1097/JCP.0b013e3181678a28
5. Steiner M, Pearlstein T, Cohen LS, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health 2006; 15:57-69
6. Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100(3):435-444. Availabel from: DOI:10.1016/s0029-7844(02)02166-x
7. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100(6):1219-1229. Available from: DOI:10.1016/s0029-7844(02)02326-8
8. Backstrom T, Andreen L, Birzniece V, Bjorn I, Johansson IM, Nordenstam-Haghjo M, Nyberg S, Sundstrom-Poromaa I, Wahlstrom G, Wang M, Zhu D. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs. 2003;17(5):325-42.
9. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O’Brien PM. The effectiveness of GnRHa with and without ’add-back’ therapy in treating premenstrual syndrome: a meta-analysis. BJOG. 2004 Jun;111(6):585-93.
10. Landen M, Eriksson E. How does premenstrual dysphoric disorder relate to depression and anxiety disorders? Depress Anxiety.
2003;17(3):122-9.
11. Sylvén SM, Ekselius L, Sundström-Poromaa I, Skalkiadou A. Premenstrual syndrom and dysphoric disorder as risk factors for postpartum depression. Acta Obstet Gynecol Scand. 2013; 92(2): 178-84. Available from: DOI:10.1111/aogs.12041.